Innovating Works

T2EVOLVE

financed
Accelerating Development and Improving Access to CAR and TCR engineered T cell t...
Accelerating Development and Improving Access to CAR and TCR engineered T cell therapy Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative novel treatment that has the potential to cure cancer. Multiple new versions of this ther... see more
31/12/2025
KLINIKUM DER BAYER...
19M€
Project Budget: 19M€
see more

Project leader
UNIVERSITAETSKLINIKUM WUERZBURG KLINIKUM DER... No se ha especificado una descripción o un objeto social para esta compañía.
TRL 4-5
PARTICIPATION DEPralty Sin fecha límite de participación.
Financing granted El organismo H2020 notifico la concesión del proyecto The day 2020-11-24
IMI2-2019-18-06: Supporting the development of engin... Specific Challenge:Engineered T cells, including chimeric antigen receptor (CAR) and T-cell receptor...
Cerrada does 5 years
0% 45% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.